Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized sto ...

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York. As a journalist, he has covered every futures market traded in the U.S., at one time or another. Jim is the proprietor of the "Jim Wyckoff on the Markets" analytical, educational and trading advisory service. Jim also worked as a ...

In this articleGS07 July 2025, USA, New York: A street sign reading "Wall Street" hangs on a post in front of the New York Stock Exchange in Manhattan's financial district. Photo: Sven Hoppe/dpa (Photo by Sven Hoppe/picture alliance via Getty Images)Picture Alliance | Picture Alliance | Getty ImagesA version of this article first appeared in CNBC's Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbo ...

Accessibility StatementSkip Navigation ENGLEWOOD, Colo., Sept. 11, 2025 /PRNewswire/ -- EchoStar Corporation (NASDAQ: SATS) will host a meeting to discuss the company's new focus on Monday, September 15, 2025, at 10 a.m. Central European Summer Time at World Space Business Week in Paris. The meeting will be broadcast live and may be accessed on EchoStar's Investor Relations website at https://ir.echostar.com/investors. A replay of the webcast will be available on the Company's Investor Relations website the ...

OPEC made no changes on Thursday to its relatively high global oil demand growth forecasts for this year and next, and said the world economy was maintaining a solid growth trend in the second half of... ...

核心观点 - 再鼎医药核心产品bemarituzumab三期临床试验结果未达预期 导致股价大幅下跌 同时公司现有产品销售增长乏力 引发市场对创新药行业整体担忧 [3][4][8][9] 临床试验进展 - bemarituzumab胃癌三期最终分析显示生存获益弱于预期 相比中期结果出现"衰减" [4] - 公司决定等待bemarituzumab联合免疫疗法nivolumab及化疗的试验数据 预计2025年底或2026年上半年公布 意味着上市申请至少延迟六个月 [5] - 该药物为全球首个在随机三期研究中显示胃癌患者显著生存获益的FGFR2b抑制剂 再鼎医药2017年以500万美元首付款及最高4000万美元里程碑付款从安进获得大中华区独家权利 [6] - 胃癌是全球高发恶性肿瘤 中国发病率尤其高 四期患者五年生存率低于10% [6] 股价表现 - 试验结果公布后 香港上市股票开盘下跌近7% 盘中跌至三个月低点22.52港元 收盘跌幅达11.99% [7] - 下跌不仅限于再鼎医药 创新药板块普遍回调 恒瑞医药和歌礼制药等生物科技公司跌幅均超过5% [9] 财务表现 - 2025年第二季度收入1.1亿美元 同比增长9% 净亏损收窄三分之一至8920万美元 [10] - 公司维持全年5.6亿至5.9亿美元收入指引 但华泰国际证券认为实现目标需要下半年同比增长63%至77% [10] - 毛利率下降4.3个百分点至60.6% 主要因核心产品销售疲软 [11] - 最畅销药物Zejula销售额4100万美元 环比下降17.1% 同比下降8.8% 主要受同类药物竞争加剧影响 [11] - 另一核心产品Vyvgart销售额2650万美元 增长14.5% 低于预期的20%至25%增幅 [12] 竞争环境 - 荣昌生物同类药物telitacicept有望纳入医保报销范围 可能加剧竞争并侵蚀Vyvgart的定价优势 [12] - 监管和定价压力收窄新药利润空间 促使公司从授权引进转向自主研发策略 [13] 研发管线 - 主要自研候选药物ZL-1310为靶向DLL3蛋白的抗体药物偶联物 用于小细胞肺癌治疗 [13] - 已获美国FDA快速通道资格 预计2025年进入关键研究 可能2027年获批 [13] 财务状况与估值 - 截至6月30日持有现金及等价物约8.3亿美元 足够支撑下半年投资和研发支出 [14] - 当前市销率约8倍 低于同样侧重授权引进模式的云顶新耀的22倍 反映市场对前景持谨慎态度 [14] - 公司预计第四季度可能实现盈利 因运营亏损收窄 [14]

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs, and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!It has been a very long period of time since I last covered shares of Illinois Tool Works (NYSE: ITW ) ; in fact, it was the summer of 2018 when I concluded that the conglomerate was on sale.As t ...

AbbVie (NYSE:ABBV) announced on Thursday that the company has reached settlements with all generic drugmakers to resolve litigation that challenged their plans to introduce copycat versions of Rinvoq, a key component in its immunology franchise. The generic drugmakers had filed ...

The market is rocketing to all-time highs nearly every day. That doesn’t mean this sugar high is going to last forever. We know what goes up must come down. One way to protect yourself when the tide turns is by sticking with stocks that have strong earnings trends and avoiding the ones with weaker trends.Today’s Bear of the Day is a stock that has seen earnings estimates come down even as the stock has jumped higher. I’m talking about Zacks Rank #5 (Strong Sell) CaliberCos (CWD) . CaliberCos might brand its ...

The American Eagle Outfitters ((AEO) earnings report announced to the world that retail is back. This helped spark a frenzy on Wall Street across the whole industry. The knee-jerk reaction has a bunch of these stocks on the move, but it’s important to find the ones with the strongest earnings trends. While stocks can pop on a dime, they can fizzle out just as quickly. One way to put the odds in your favor is by leaning on the Zacks Rank.Today’s Bull of the Day is a stock that’s in the good graces of our Zac ...